Concepedia

Mohamed Kazamel

MK

Statistics

Publications

17

Citations

1.4K

H-Index

16

Active since

2013

Affiliations

University of Alabama at Birmingham(Current)

Birmingham VA Medical Center

University of Miami

Alexion Pharmaceuticals (United States)

Stanford University

Mohamed Kazamel is an author at University of Alabama at Birmingham specializing in medicine, amyotrophic lateral sclerosis, and neurodegenerative disorders.

ORCID

Publications per year

2013–2023

17

Publications

17

Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study

James F. Howard, Kimiaki Utsugisawa, Michael Benatar et al. · The Lancet Neurology · 2017 · 800 citations

, , +6

Comprehensive immune profiling reveals substantial immune system alterations in a subset of patients with amyotrophic lateral sclerosis

Michael P. Gustafson, Nathan P. Staff, Svetlana Bornschlegl et al. · PLoS ONE · 2017 · 94 citations · Full text

, , +17

Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension

Renato Mantegazza, Gil I. Wolfe, Srikanth Muppidi et al. · Neurology · 2020 · 79 citations · Full text

, , +9

Eculizumab improves fatigue in refractory generalized myasthenia gravis

Henning Andersen, Renato Mantegazza, Jing Jing Wang et al. · Quality of Life Research · 2019 · 56 citations · Full text

, , +14

Muscle microRNA signatures as biomarkers of disease progression in amyotrophic lateral sclerosis

Ying Si, Xianqin Cui, David K. Crossman et al. · Neurobiology of Disease · 2018 · 49 citations · Full text

, , +16

1–5 of 17